Senior Clinical Data Manager

Net Health acquired Keet Health from WebPT | Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research. Check out today's featured companies who have recently completed an M&A deal, and be sure to check out the full list of past healthcare IT M&A. Net Health Advances Rehab Therapy Care with Acquisition of Keet Health from WebPT Net Health, a trusted provider of specialized software for rehab therapy and post-acute care, today announced the acquisition of Keet Health, a WebPT company, as part of a strategic collaboration with WebPT focused on advancing outcomes measurement and remote therapeutic monitoring (RTM) for rehabilitation therapy providers. Net Health's acquisition of Keet Health expands access to Net Health's Limber platform - the industry's leading solution for outcomes measurement, RTM, and digital home exercise programs. In connection with the transaction, Limber will become the preferred outcomes and RTM solution for WebPT and Clinicient customers, with an integrated experience targeted for early 2026. "Better outcomes are driven by better insights and stronger connections across the continuum of care," said Ron Books, CEO at Net Health. "Through our collaboration with WebPT, we're advancing outcomes measurement and remote monitoring in ways that help rehab providers extend care beyond the clinic, reduce fragmentation, and keep the focus where it belongs - on patients." Limber, which Net Health acquired in 2025, is a leading platform for outcomes measurement, RTM enablement, and home exercise delivery for rehab therapy providers. The solution delivers outcomes-informed insights that help clinicians monitor progress, personalize care, and support patients beyond traditional clinic visits. Net Health continues to invest in Limber's analytics and integration capabilities as part of its broader platform strategy to support value-based care. Net Health and WebPT also plan to invest in deeper integration between Limber and the WebPT and Clinicient platforms. The integration is intended to streamline workflows, strengthen data continuity, and support more connected digital health experiences as patients transition between care settings. "Our work with Net Health gives our members access to a powerful digital health solution while preserving the flexibility and choice they expect," said Andrea Facini, CEO at WebPT... Full release here, originally announced January 15th, 2026. Worldwide Clinical Trials Enters Definitive Agreement to Acquire Catalyst Clinical Research Worldwide Clinical Trials, a global contract research organization (CRO), has entered into a definitive agreement to acquire Catalyst Clinical Research, LLC, a specialized oncology CRO, known for its expertise in early phase oncology trials and a strong biometrics and Functional Service Provider (FSP) model. Following the close of the transaction, Nick Dyer, Chairman of the Board at Catalyst, will join Worldwide's Board of Directors, and Nik Morton, President and CEO at Catalyst, will join Worldwide's executive leadership team. This strategic combination creates immediate value for customers by establishing Worldwide as a leading oncology-focused CRO, while maintaining depth across multiple therapeutic areas and strengthening its footprint and scale to deliver larger global trials. The integration of Catalyst's two established solutions - Catalyst Oncology and Catalyst Flex - will strengthen Worldwide's portfolio, offering customers proven expertise and new services for full-service, FSP resourcing, and hybrid solutions. Additionally, the integration of complementary technology platforms and best-in-class operational practices will enable enhanced data visibility and improved efficiency throughout the development lifecycle - helping customers bring life-changing therapies to patients more quickly. "Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers," said Alistair Macdonald, Chief Executive Officer at Worldwide. "We are excited to add Catalyst's deep operational expertise and oncology credibility to our own well-known CNS specialist CRO capabilities to create a differentiated biotech-oriented oncology solution. Our combined customers seek focused senior executive connection and attention, predictability, speed, flexibility, and scientific rigor. They will benefit from the addition of a scalable FSP model with integrated onshore/offshore service lines, while we leverage advanced business management tools and AI to drive operational excellence. Beyond the science, this is about people - bringing together talented teams, expanding opportunities, and working together to deliver more agile trials for our customers." Matt Jennings, Executive Chairman at Worldwide and Senior Operating Partner at Kohlberg, the majority owner of the Company, commented, "Integrating Catalyst will accelerate Worldwide's growth in oncology and expand both its customer base and global reach simultaneously. Their specialized expertise, innovative platforms, and strong relationships with emerging biotech sponsors align perfectly with our vision for building a differentiated, technology-enabled CRO. This is a strategic step toward creating a more agile and competitive organization that can meet the evolving needs of clinical research globally." "This marks an exciting new chapter for both Catalyst and Worldwide. By joining forces, Catalyst brings our specialized early phase oncology expertise together with Worldwide's strength in late phase development, expanding our global footprint and delivering differentiated oncology solutions globally," said Nik Morton, President and Chief Executive Officer at Catalyst... Full release here, originally announced January 20th, 2026.

Worldwide Clinical Trials to acquire Catalyst Clinical Research. Two North Carolina-based contract research organizations (CROs) are joining forces to provide expanded clinical trial services in oncology. Worldwide Clinical Trials, a full-service, global CRO headquartered in Research Triangle Park, has entered into a definitive agreement to acquire Wilmington-based Catalyst Clinical Research, a global CRO with expertise in cancer. "Bringing Worldwide and Catalyst together elevates our capabilities in oncology and provides a new solution for our collective customers," said Alistair Macdonald, chief executive officer of Worldwide. "Beyond the science, this is about people - bringing together talented teams, expanding opportunities, and working together to deliver more agile trials for our customers." Worldwide will acquire Catalyst for an undisclosed amount. The transaction is expected to close in the first quarter of 2026. "This marks an exciting new chapter for both Catalyst and Worldwide," said Nik Morton, president and chief executive officer of Catalyst. "By joining forces, Catalyst brings our specialized early phase oncology expertise together with Worldwide's strength in late phase development, expanding our global footprint and delivering differentiated oncology solutions globally." As part of the acquisition, Morton will join Worldwide's executive leadership team, and Nick Dyer, chairman of the board of Catalyst, will join Worldwide's board of directors. The two companies said their strategic combination would create immediate value for customers by establishing Worldwide as a leading oncology-focused CRO, while maintaining depth across multiple therapeutic areas and strengthening its footprint and scale to deliver larger global trials. Matt Jennings, executive chairman of Worldwide and senior operating partner of the private equity firm Kohlberg, the majority owner of the company, said, "Integrating Catalyst will accelerate Worldwide's growth in oncology and expand both its customer base and global reach simultaneously. Their specialized expertise, innovative platforms, and strong relationships with emerging biotech sponsors align perfectly with our vision for building a differentiated, technology-enabled CRO. This is a strategic step toward creating a more agile and competitive organization that can meet the evolving needs of clinical research globally." Worldwide, founded in 1986, has over 3,500 employees working in more than 60 countries in North and South America, Europe and Asia. Its capabilities include bioanalytical laboratory services, Phase I-IV clinical trials, and post-approval and real-world evidence studies. Worldwide is therapeutically focused on neuroscience, oncology, rare disease, and cardiometabolic and inflammatory disease. Catalyst, founded in 2013, has more than 1,000 staff and several offices in the United States, Europe, and the Asia-Pacific region. It is owned by QHP Capital, a health care and life sciences private equity firm based in Research Triangle Park.